Dr Gunter’s research focuses on the role of nutrition, diabetes, and obesity in the natural history of cancer with an emphasis on metabolic dysfunction and in particular the insulin/IGF/mTOR pathway. He is principal investigator of a number of studies applying high dimensional metabolic profiling within the framework of large prospective and clinical cohorts, as well as intervention studies, to identify novel biochemical pathways involved in cancer development and prognosis. He is currently co-PI of the European Prospective Investigation into Cancer (EPIC) – a multinational cohort of over 520,000 Europeans and since 2019 is a steering committee member of the NCI Cohort Consortium which includes more than 50 prospective cohort studies worldwide. He has published more than 450 scientific articles and book chapters and serves on numerous committees and panels for international organizations such as the World Cancer Research Fund.